Abstract:
Objective To explore the safety and preliminary efficacy of deep hyperthermia combined with 5-Fu and DDP intraperitoneal chemotherapy in the adjuvant treatment of pseudomyxoma peritonei (PMP).
Methods We performed a retrospective analysis for the clinical data and follow-up results of the patients who received the treatment of deep hyperthermia combined with intraperitoneal chemotherapy in Aerospace Center Hospital from January 2018 to December 2019. The blood routine examination, blood biochemical examination (hepatic and kidney function examination), Karnofsky score and complications of the patients were collected. Combined with the follow-up results, we evaluated the safety and preliminary efficacy of deep hyperthermia combined with intraperitoneal chemotherapy on PMP.
Results A total of 58 patients with PMP were included in this study. There was no significant difference in white blood cell (WBC) (P=0.064), hemoglobin (HGB) (P=0.47), aspartate aminotransferase (AST) (P=0.08) and creatinine(CREA) (P=0.68) before and after treatment. There were statistical differences in alanine aminotransferase (ALT) (P=0.01), percentage of neutrophils (NE%) (P=0.001), absolute value of neutrophils (NE#) (P=0.004), blood urea nitrogen (BUN) (P=0.000) and Karnofsky score (P=0.017) before and after treatment. Further analysis of the average changes showed that neutrophil level (NE%, NE#) and quality of life (Karnofsky score) were improved compared with those before treatment. ALT and BUN were lower than before treatment. The total incidence of adverse reactions was 24.1% (Grade 1: 20.7%, Grade 2: 3.4%). The 1-year and 2-year survival rates were 100% and 96.4%, respectively.
Conclusions Deep hyperthermia combined with 5-Fu and DDP intraperitoneal chemotherapy is a safe and preliminary effective treatment for PMP, which does not damage the liver and kidney function, has no obvious bone marrow suppression, does not reduce the quality of life, and the adverse reactions are controllable.